TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06234007
Drug: Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety run-in phase: Fruquintinib 4mg/d, oral, once daily, continuous treatment for 2 weeks, 1 week off, q3w, 6 cycles; If the number of patients experiencing dose-limiting toxicity (DLT) was ≤1, the study would continue at that dose level. If the number of patients with DLTs was \>1, the dose of fruquintinib was decreased to 3mg/d, qd po, d1-14, q3w, and the dose expansion phase was continued；Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;~Dose expansion phase: Fruquintinib RP2D, qd po, d1-14, q3w, 6 cycles; Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;
Study: NCT05606497
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal corticosteroids are administered to pregnancies at risk for preterm birth in order to reduce risks of neonatal morbidity and mortality following preterm birth.
Study: NCT04920916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline.
Study: NCT04724044
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets of 500mg of clarithromycin
Study: NCT06019520
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol.
Study: NCT00006235
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06136754
Drug: Varnishes, Fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish containing 5.0% NaF
Study: NCT06127368
Drug: Oral cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Aricept tablet.
Study: NCT05476107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or daily dosing at doses A, B, C, D, E, F; G,H, and I
Study: NCT05226559
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacological treatment alone.
Study: NCT05217706
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will receive normal saline IV in a matched syringe
Study: NCT04874675
Drug: ibuprofen/acetaminophen/codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine pain medication used post extraction of third molars
Study: NCT05914935
Drug: Recombinant L-IFN adenovirus injection
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Ommaya reservoir was surgically implanted, and multiple intracapsular injections were given medicine. On the second day after Ommaya reservoir implantation, CT examination confirmed that the implantation was successful, and the experimental drug injection was started.
Study: NCT05385159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose tissue removal, ADSVF production, cryopreservation of ADSVF and injection of placebo will be done on the same day during a short hospital stay.
Study: NCT05028049
Drug: Sufentanil injection
Normalized name: sufentanil Injection
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia
Study: NCT05028049
Drug: Remifentanil Hydrochloride
Normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia
Study: NCT04727437
Drug: direct oral anticoagulants
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: anticoagulation drug given for at least 3 months.
Study: NCT04727437
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: anticoagulation drug, subcutaneous injection given for at least 3 months.
Study: NCT05569941
Drug: ABI-4334 Tablet
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-4334 Tablet
Study: NCT05569941
Drug: ABI-4334 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to ABI-4334 Tablet
Study: NCT06077331
Drug: HS-10374-matched placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally QD for 12 weeks
Study: NCT06484634
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.
Study: NCT06531369
Drug: Saline（C group）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil Injection（F2 group）: Immediately after surgery, an equal volume of saline (equal to the volume of 0.5 mg flumazenil) was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
Study: NCT05701644
Drug: C1K 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15
Study: NCT05701644
Drug: C1K 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administrate C1K 300mg at Day 1, Day 8, Day 15
Study: NCT05701644
Drug: C1K 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administrate C1K 600mg at Day 1, Day 8, Day 15
Study: NCT05701644
Drug: C1K 900mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administrate C1K 900mg at Day 1, Day 8, Day 15
Study: NCT05701644
Drug: C1K 1200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administrate C1K 1200mg at Day 1, Day 8, Day 15
Study: NCT05230537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules
Study: NCT00017160
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06071988
Drug: Adezunap (AP707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
Study: NCT06071988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Study: NCT05596721
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treat patient with azithromycin for 12w.
Study: NCT05596721
Drug: ICS/LABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat patient with ICS/LABA according to Global Initiative for Asthma (GINA) guideline.
Study: NCT06237491
Drug: 177Lu-LNC1003 Injection group 1
Normalized name: meningococcal group B vaccine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment regimen will consist of a single dose 30 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
Study: NCT06237491
Drug: 177Lu-LNC1003 Injection group 2
Normalized name: meningococcal group B vaccine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment regimen will consist of a single dose 50 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
Study: NCT06237491
Drug: 177Lu-LNC1003 Injection group 3
Normalized name: meningococcal group B vaccine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment regimen will consist of a single dose 70 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
Study: NCT05865080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT04979273
Drug: Adrenaline 1 Mg/mL Solution for Injection
Normalized name: Adrenaline 1 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
Study: NCT06391164
Drug: XC243 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the Investigated Product (IP) once in the morning at least 30 minutes before eating for 7-10 days
Study: NCT06391164
Drug: XC243 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
Study: NCT06391164
Drug: XC243 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
Study: NCT06391164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
Study: NCT05993143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Round and white tablets
Study: NCT05061017
Drug: Cyclophosphamide (low dose)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is approved by the FDA for the treatment of acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, breast cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, multiple myeloma, mycosis fungoides, neuroblastoma, non-Hodgkin lymphoma, ovarian cancer, retinoblastoma. Low-dose (immunomodulatory) cyclophosphamide is being studied in combination with various types of immunotherapy including nivolumab and pembrolizumab
Study: NCT06151496
Drug: Alpha-Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Study: NCT06151496
Drug: α-adrenergic receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Study: NCT05194878
Drug: neoadjuvant chemotherapyI
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOXIRI (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV Irinotecan 150 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 48h every 14 days) for 6 cycles followed by colectomy (3 to 6 weeks after) . If PD was observed after 3 cycles, direct colectomy was performed.
Study: NCT05194878
Drug: adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) . CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) . Oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days. The plan and cycles are determined according to the surgical pathology and physical conditions.
Study: NCT05494918
Drug: JSKN003
Approvals — FDA: no, EMA: no, PMDA: no
Description: JSKN003 is to be administered via intravenous (IV) dose
Study: NCT05840406
Drug: Postoperative pain management with acetaminophen
Normalized name: acetaminophen / diphenhydramine Oral Tablet [Unisom with Pain Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the 24 hours postoperatively, participants will receive 1 g acetaminophen intravenously (i.v.) three times a day. On the second and third postoperative days, participants will receive 1g acetaminophen per os three times a day.
Study: NCT05840406
Drug: Postoperative pain management with ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the 24 hours postoperatively, participants will receive 100 mg ketoprofen + 100 ml of 0,9% NaCl i.v. twice a day. The first dose will be administered in the theatre at the end of the surgical procedure.
Study: NCT05840406
Drug: Postoperative pain management with ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the second and third postoperative days, participants will receive 600 mg ibuprofen per os three times a day.
Study: NCT05372783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent solution
Study: NCT06412588
Drug: Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Group A:The patient was treated with oral Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid + doxycycline 0.1 g, bid + bismuth for 14 days.
Study: NCT06412588
Drug: Vonoprazan+doxycycline
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Group C: Patients were treated with oral Vonoprazan 20 mg, bid + doxycycline 0.1 g, bid for 14 days.
Study: NCT06606899
Drug: Melatonin 3 MG
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral syrup melatonin 3 mg
Study: NCT05438498
Drug: Evusheld (tixagevimab+cilgavimab) IM or IV
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evusheld (tixagevimab 300 mg +cilgavimab 300 mg) IM or IV
Study: NCT05142098
Drug: Etoricoxib 60 mg
Normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally
Study: NCT06141161
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhailed or oral corticosteroids
Study: NCT05033912
Drug: CST-2032, matching placebo for CST-2032, CST-107
Approvals — FDA: no, EMA: no, PMDA: no
Description: CST-2032 and matching placebo oral liquid; CST-107 white capsules
Study: NCT05426304
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 25 mg/day for 180 days
Study: NCT04970108
Drug: Egito
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EGITO Egito coated tablet. EMPAGLIFLOZIN PLACEBO Empagliflozin placebo coated tablet. TELMISARTAN PLACEBO Telmisartan coated tablet.
Study: NCT05791682
Drug: Sealant, Fissure
Approvals — FDA: no, EMA: no, PMDA: no
Description: FISSURIT FX- MICROFILLED RESIN SEALANT WITH 55% FILLER GRANDIOSEAL- NANOFILLED RESIN SEALANT WITH 70% FILLER TE-ECONOM- FLOW -FLOWABLE COMPOSITE AS SEALANT CLINPRO TM- UNFILLED RESIN SEALANT
Study: NCT05979363
Drug: VRD-based regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib, Lenalidomide and Dexamethasone
Study: NCT04746911
Drug: ARQ-151 cream 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
Study: NCT04753177
Drug: Doxorubicin, cyclophosphamide, paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
Study: NCT04674748
Drug: INCB086550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each Participant will be treated at the specified dose level with a minimum of 3 subjects at each dose level. After the RP2D of INCB086550 is identified, the dose level will be expanded to better characterize the safety and tolerability and PK.
Study: NCT05892939
Drug: intranasal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of intranasal Placebo
Study: NCT04301284
Drug: CAD-1883
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg filled capsules
Study: NCT04301284
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT04972123
Drug: CPC - Capsaicin, Phenylephrine, Caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPC is a combination of Capsaicin, Phenylephrine and Caffeine
Study: NCT04972123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for CPC
Study: NCT05114837
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 500 mg/m\^2 is administered as an IV infusion per institutional guidelines once a day on 2 consecutive days (Day -5, and Day -4)
Study: NCT05167604
Drug: Adjuvants, Pharmaceutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with stage IB-IIA NSCLC after curative surgery were treated with adjuvant chemotherapy. The blood samples of the patients before and after adjuvant chemotherapy will be collected to examine the MRD status
Study: NCT05656521
Drug: 101-PGC-005
Approvals — FDA: no, EMA: no, PMDA: no
Description: '005 is a targeted prodrug of dexamethasone that binds to activated macrophages.
Study: NCT05426525
Drug: Multivitamin-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take 1 multivitamin per day for 13 weeks.
Study: NCT06532942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo across Part A and Part B of the study.
Study: NCT04719507
Drug: Pethidine Only Product in Parenteral Dose Form
Normalized name: Pethidine only product in parenteral dose form
Approvals — FDA: no, EMA: no, PMDA: no
Description: pethidine (1 mg/kg ) once
Study: NCT06367855
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT06597500
Drug: GSK3923868
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3923868 will be administered.
Study: NCT05351554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously to match namilumab dosing
Study: NCT04784754
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin capsules will be prepared using hypromellose capsules containing 3 mg or 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
Study: NCT04784754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
Study: NCT05483595
Drug: Chinese herbal medicine FYTF-919
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid 10ml
Study: NCT06490445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered using Fixed-dose Syqe Inhaler.
Study: NCT05056883
Drug: K-237 0.3-0.4mg/kg (once daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 3mg tablet
Study: NCT05056883
Drug: Placebo 0.3-0.4mg/kg (once daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3mg tablet
Study: NCT05927272
Drug: Systemic Steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral minipuls of systemic steroids (Medrol 16mg twice a week) for 24 weeks
Study: NCT04493320
Drug: Carbidopa/levodopa
Normalized name: CARBIDOPA/LEVODOPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-450mg carbidopa/levodopa 3 times daily
Study: NCT04493320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa/levodopa-matched placebo tablet 3 times daily
Study: NCT05670782
Drug: KM-819
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral doses of KM-819 once-daily
Study: NCT05670782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo once-daily
Study: NCT05990153
Drug: clinical practice drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug treatment according to the medical indications of clinical practice
Study: NCT05578196
Drug: fecal bacteria solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.
Study: NCT05578196
Drug: physiological saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological saline solution 20ml
Study: NCT04635826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered placebo
Study: NCT05243953
Drug: Levcromakalim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min (20 ml of 50 mg/ml) levcromakalim.
Study: NCT05243953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
Study: NCT04601610
Drug: KN046 （PD-L1/CTLA4 BsAb）
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN046 5mg/kg Q3W
Study: NCT04969510
Drug: 10 mg PRAX-114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment
Study: NCT04969510
Drug: 20 mg PRAX-114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment
Study: NCT04969510
Drug: 40 mg PRAX-114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment
Study: NCT04969510
Drug: 60 mg PRAX-114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment
Study: NCT04969510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment
Study: NCT00000717
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04617054
Drug: AB-106
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg QD for each subjects.
Study: NCT04853992
Drug: LEO 152020
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.
Study: NCT04853992
Drug: LEO 152020 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.